Efficacy of oral treatment with BV-araU against cutaneous infection with herpes simplex type 1 in shaved mice.

The effect of oral BV-araU was tested in cutaneous model infections of shaved Balb/c mice with herpes simplex virus type 1 (HSV-1). Progression of cutaneous symptoms associated with cutaneous infection with HSV-1 F strain was inhibited by BV-araU at doses of 20 and 50 mg/kg twice daily, beginning one day post-infection, resulting in significant increase in the survival rate. Onset of disease was suppressed in most animals receiving 100 mg of BV-araU per kg. BV-araU (20 mg/kg or more) also significantly increased the survival rate of mice infected with HSV-1 WT-51 strain. The efficacy of BV-araU was not affected by gender or age (6-9 weeks) of the mice. BV-araU was effective even when the treatment was started 2.5 days post-infection. The efficacy of BV-araU against F strain infection was comparable to that of acyclovir, but acyclovir showed therapeutic effects at lower doses compared with BV-araU against WT-51 strain infection. Against infection of cyclophosphamide-treated immunosuppressed mice with HSV-1 KOS(S) strain, BV-araU decreased the morbidity rate and severity of symptoms at doses of 200 and 100 mg/kg, respectively, and all mice given 50 mg of BV-araU or more per kg survived, suggesting oral efficacy can be achieved against HSV-1 infections in immunosuppressed individuals.
AuthorsH Machida, K Ijichi, J Takezawa
JournalAntiviral research (Antiviral Res) Vol. 17 Issue 2 Pg. 133-43 (Feb 1992) ISSN: 0166-3542 [Print] NETHERLANDS
PMID1554238 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Antiviral Agents
  • Arabinofuranosyluracil
  • sorivudine
  • Acyclovir
  • Acyclovir (therapeutic use)
  • Administration, Oral
  • Animals
  • Antiviral Agents (administration & dosage, therapeutic use)
  • Arabinofuranosyluracil (administration & dosage, analogs & derivatives, therapeutic use)
  • Disease Models, Animal
  • Drug Administration Schedule
  • Drug Evaluation, Preclinical
  • Female
  • Herpes Simplex (drug therapy)
  • Immune Tolerance
  • Male
  • Mice
  • Mice, Inbred BALB C

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: